CoChat

Cost-effectiveness analysis of initiating type 2 diabetes therapy with a sodium-glucose cotransporter 2 inhibitor versus conventional therapy in Japan

Open access
Igarashi, Ataru, Maruyama-Sakurai, Keiko, Kubota, Anna, Akiyama, Hiroki, Yajima, Toshitaka, Kohsaka, Shun, Miyata, Hiroaki · 2022 · Diabetes Therapy

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Many patients with type 2 diabetes mellitus (T2DM) suffer from complications that impose substantial burdens on prognosis and medical costs. Accumulating evidence has demonstrated the clinical benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular and renal complications. However, the health economic impact of SGLT2i remains unclear. The aim of this study was to evaluate the cost-effectiveness of initiating antidiabetic therapy with an SGLT2i using Japanese real-world data. METHODS: We constructed a natural history model incorporating heart failure (HF), myocardial infarction, stroke, chronic kidney disease, and end-stage renal disease (ESRD) as complications. The target population comprised patients with T2DM who newly initiated their first oral glucose-lowering drugs. By using a population-based microsimulation, we estimated the 10-year medical costs in Japanese yen (JPY) and outcomes (hospitalization for/development of complications and quality-adjusted life years [QALY]) for patients who initiated antidiabetic therapy with an SGLT2i or conventional therapy. Sensitivity analyses included a probabilistic sensitivity analysis (PSA) with 1,000,000 iterations. RESULTS: In the base-case analysis, the total medical cost per person was JPY 1,638,806 versus JPY 1,825,033 and the QALYs were 8.732 versus 8.513 for the SGLT2i strategy versus the conventional strategy, respectively. Thus, initiating treatment with an SGLT2i was dominant, more effective (QALY gain), and lower cost. When treating 10,000 patients, the SGLT2i strategy would reduce all-cause deaths by 410 (552 vs 962), HF events by 201 (897 vs 1098), and ESRD events by 16 (16 vs 32) versus the conventional strategy. The PSA revealed that the probability of dominance for initiating SGLT2i therapy was 90.5%, demonstrating the robustness of the results. CONCLUSION: Our results suggest that initiating T2DM treatment with SGLT2i, aimed at managing cardiovascular and renal complications from the early stages of diabetes, can improve the clinical outcome and reduce cost burden of T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-022-01270-8

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Model structure. CKD chronic kidney disease, ESRD end-stage renal disease, HF heart failure, MI myocardial infarction
Fig. 1 Model structure. CKD chronic kidney disease, ESRD end-stage renal disease, HF heart failure, MI myocardial infarctionCC BY-NC · PubMed Central
Fig. 2 Breakdown of costs. CKD chronic kidney disease, ESRD end-stage renal disease, HF heart failure, JPY Japanese yen, MI myocardial infarction, SGLT2i sodium–glucose cotransporter 2 inhibitor
Fig. 2 Breakdown of costs. CKD chronic kidney disease, ESRD end-stage renal disease, HF heart failure, JPY Japanese yen, MI myocardial infarction, SGLT2i sodium–glucose cotransporter 2 inhibitorCC BY-NC · PubMed Central
Fig. 3 One-way sensitivity analysis. The tornado plot shows the incremental cost-effectiveness ratio for each model input parameter. EV equivalent variation, HF heart failure, MI myocardial infarction, NMB net monetary benefit, QOL quality of life, SGLT2i sodium–glucose cotransporter 2 inhibitor
Fig. 3 One-way sensitivity analysis. The tornado plot shows the incremental cost-effectiveness ratio for each model input parameter. EV equivalent variation, HF heart failure, MI myocardial infarction, NMB net monetary benefit, QOL quality of life, SGLT2i sodium–glucose cotransporter 2 inhibitorCC BY-NC · PubMed Central
Fig. 4 Probabilistic sensitivity analysis. The scatterplot shows results of 1,000,000 Monte Carlo simulations in the cost-effectiveness plane. ICER incremental cost-effectiveness ratio, JPY Japanese yen, QALY quality-adjusted life years, SGLT2i sodium–glucose cotransporter 2 inhibitor
Fig. 4 Probabilistic sensitivity analysis. The scatterplot shows results of 1,000,000 Monte Carlo simulations in the cost-effectiveness plane. ICER incremental cost-effectiveness ratio, JPY Japanese yen, QALY quality-adjusted life years, SGLT2i sodium–glucose cotransporter 2 inhibitorCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Research works printed but not linked: 1

  1. Toyonaga T. Factors affecting the sot for medical care and rehabilitation in stroke patients. Jpn Soc Occup Med Traumatol. 2006;54:175–82.

Cited by

See all 17

Metadata

Authors
Igarashi, A., Maruyama-Sakurai, K., Kubota, A., Akiyama, H., Yajima, T., Kohsaka, S., & Miyata, H.
Affiliations
  • Keio University (JP)
  • AstraZeneca (Japan) (JP)
Corresponding author
Igarashi, Ataru
Venue
Diabetes Therapy
Published
2022-06-16
Volume
13
Issue
7
Pages
1367-1381
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4282977603
Cited by
17
References
57
Citations by year
2025: 5 · 2024: 4 · 2023: 7 · 2022: 1
FWCI
3.15
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • AstraZeneca
  • Japan Science and Technology Corporation (JPMJOP1842)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
type 2 diabetes, SGLT2 inhibitors, cost-effectiveness, cardiovascular complications, renal complications, heart failure, end-stage renal disease, chronic kidney disease, quality-adjusted life years, health care costs, natural history model, microsimulation, Japan

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-effectiveness analysis of initiating type 2 diabetes therapy with a sodium-glucose cotransporter 2 inhibitor versus conventional therapy in Japan. https://app.cochat.ai/papers/10.1007/s13300-022-01270-8
The paper
Igarashi, A., Maruyama-Sakurai, K., Kubota, A., Akiyama, H., Yajima, T., Kohsaka, S., & Miyata, H. (2022). Cost-effectiveness analysis of initiating type 2 diabetes therapy with a sodium-glucose cotransporter 2 inhibitor versus conventional therapy in Japan. Diabetes Therapy. https://doi.org/10.1007/s13300-022-01270-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.